Cramer: This biotech stock could be worth over $100 billion on an FDA approval
October 30, 2019 at 19:34 PM EDT
Biogen, with a $54.1 billion market cap, "could be worth twice that if all goes well" with regulators, Jim Cramer says.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|